News and Announcements
MHRA Approves Commencement of OncoSil’s Study of Pancreatic Cancer Clinical Study in UK
- Published February 21, 2017 11:32AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX:OSL) is a medical device company seeking to advance radiation for cancer patients.
KEY TAKEAWAYS:
- Medical device company is mainly focused on localised treatments for patients with pancreatic and liver cancer.
- MHRA has approved the commencement of the Pancreatic Cancer Clinical Study in the UK.
OncoSil Medical Limited is a clinical-stage Australian Lifesciences company with the aim to develop and provide technologies for safer medical radiation treatments.
“The comprehensive MHRA review conducted over the past two months, focused on pre-clinical, clinical data as well study design. Approval was granted with no objections raised.
Daniel Kenny, CEO commented:
We are delighted with this news, which is a further endorsement of our clinical data package and allows OncoSil Medical to commence Clinical Studies in the UK.”
OncoSil Medical hopes with treatment of OncoSil™ it will deliver a more concentrated localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical studies with encouraging results on tolerability, safety and efficacy.
To view the full ASX Announcement, please click here.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
